Abstracts Clinical Lymphoma, Myeloma & Leukemia September 2023 S514 stem cell (HSC) mobilization, neutrophils and platelet engraftment; as well as risk of post-transplant infections. Objective: The present study aims to investigate effect of daratumumab exposure on the HSC collected, neutrophil and platelet engraftment, in addition to the risk of infections post autologous stem cell transplant (ASCT) in patients with MM receiving upfront transplant. Design: This is a single center, retrospective study of MM patients who underwent ASCT between January 2020 and March 2023 at the American University of Beirut Medical Center in Lebanon, and had received proteasome inhibitor, in combination with an immunomodulatory agent, and dexamethasone, with (daratumumab-based) or without addition of daratumumab (triplet group). Outcome Measures: Total stem cells collected, days to neutrophil and platelet engraftment; number and type of post ASCT infection. Data related to patient and disease characteristics were collected, treatment lines, treatment regimens, number of stem cells collected, use of plerixafor, total melphalan dose among others. Results: 56 patients were identified; 24 (42.85%) received daratumumab-based regimen (as quadruplets), as pre-transplant induction. Median age for daratumumab-based group was 54.8, around 70% being older than 50 years. 8 patients (33.3%) in daratumumab-based group required addition of plerixafor (for failed or inadequate mobilization), compared to 10 patients (31.3%) in triplet group (p-value 0.039). Median stem cells collected was 3x106/kg in both groups (P-value 0.8). Median days to neutrophil engraftment was 12 days in daratumumab-based group and 11 days in triplet group (P-value 0.07), while median to platelet engraftment was 17 and 18 days respectively (P-value 0.7). Regarding post-transplant infections, 7 patients (29%) had infection within 60 days post-transplant in daratumumab-based group compared to 14 patients (42.85%) in triplet group without statistical significance (P-value 0.18). Conclusions: The use of daratumumab does not seem to significantly affect yield of HSC mobilization, neutrophil or platelet engraftment, with a non-significant decreased risk of posttransplant infections for patients with NDMM. Keywords: MM, daratumumab, autologous stem cell transplant, engraftment MM-645 Incidence of Brain Cancer Among Waldenstrom Macroglobulinemia (WM) Survivors: Analysis of the SEER Database (2000‑2019) Alankrita Taneja MBBS1, Rahul Mishra MBBS2, Ajay Iyer MBBS3 1Buffalo, Buffalo, USA. 2Cleveland Clinic, Cleveland, USA. 3HCA Kansas City/Overland Park Regional Medical Center Program, Kansas, USA Background: WM is an indolent disease with a median survival of up to 16 years following diagnosis. We aimed to focus our study on the incidence of brain cancer among patients surviving WM, in order to identify further risk factors which can help in their targeted surveillance. Methods: We used the SEER 17 registry to identify adult patients (pts) with an index diagnosis (dx) of WM between 2000 and 2019. We excluded patients with diagnosis made from death certificate or autopsy. Follow-up period was till December 2019. Demographics and treatment details were extracted using SEER Stat v 8.4.0.1 software. Statistical analyses were performed using R 4.2.2. Chi-squared test was used to calculate difference between categorical variables. Kaplan Meier method and log rank test were used to estimate overall survival (OS). Results: We identified 8099 patients with a dx of WM, of which 16 (0.19%) had subsequent brain cancer. WM and brain cancer were diagnosed at median (IQR) ages of 65 (64-71) y and 74 (70-79) y, with a median interval of 62 (39-92) months. Majority of WM survivors with brain cancer were males (62%), white (87%) and old (>60y) (93%) at WM diagnosis. The most common type of brain cancer was glioblastoma (68%). The median survival after brain cancer diagnosis was 7 months and the standardized incidence ratio (SIR) for brain cancer in WM survivors was 2.07 (1.18-3.37). Conclusion: There was a low (0.19%) incidence of brain cancer in WM survivors during 2000-2019 which was 2% of all solid malignancies in WM survivors during that period. It was mostly seen in older, white males and prior chemotherapy had no effect on the incidence of brain cancer. This study provides the basis for consideration of the surveillance for brain cancer in WM survivors as per clinical correlation of symptoms. Keywords: MM, Waldenstrom macroglobulinemia, plasma cell disorders, multiple myeloma, survivorship Cellular Therapy CT-045 Primary Results From OUTREACH: A Phase II Study of Lisocabtagene Maraleucel (Liso‑Cel) Administered in the Community Setting as Outpatient or Inpatient Treatment in Patients With Relapsed or Refractory (R/R) Large B‑Cell Lymphoma (LBCL) Yuliya Linhares MD1, Cesar Freytes MD2, Mohamad Cherry MD, MS3, Carlos Bachier MD2, Michael Maris MD4, Daanish Hoda MD5, Juan C. Varela MD, PhD6, Courtney Bellomo MD7, Scott Cross MD8, James Essell MD9, Suzanne Fanning DO10, Howard Terebelo DO11, Habte Yimer MD12, Jay Courtright MD13, Jeff P. Sharman MD14, Ana Kostic MD15, Min Vedal PhD15, Ken Ogasawara PhD, MPH16, Ariel Avilion PhD15, Ricardo Espinola MD17, Brenda Yuan PharmD16, Bassam Mattar MD, FACP18 1Baptist Health, Miami Cancer Institute, Miami, USA. 2Sarah Cannon Transplant & Cellular Therapy Program at Methodist Hospital, San Antonio, USA. 3Atlantic Health System, Carol Simon Cancer Center, Morristown, USA. 4Colorado Blood and Cancer Institute and Sarah Cannon Research Institute, Denver, USA. 5Intermountain Healthcare, Loveland Clinic for Blood Cancer Therapy, Salt Lake City, USA. 6Advent Health, Orlando, USA. 7New York Oncology Hematology, Albany, USA. 8Virginia Oncology Associates, Norfolk, USA. 9Oncology Hematology Care, Cincinnati, USA. 10Prisma Health, Greenville, USA. 11Ascension St. John Newland Medical Associates, Southfield, USA. 12Texas Oncology-Tyler, Tyler, USA. 13Texas Oncology, Medical City
RkJQdWJsaXNoZXIy MTk3NTQxMg==